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he Effects of Testicular Cancer
reatment on Health-related Quality of Life
amon J. Vidrine, Josette E. H. M. Hoekstra-Weebers, Harald J. Hoekstra,
arrit A. Tuinman, Salma Marani, and Ellen R. Gritz
BJECTIVES To prospectively describe the effects of adjuvant chemotherapy on health-related quality of life
(HRQOL) among men with newly diagnosed non–seminoma germ cell tumors of the testis.
Several characteristics of testicular cancer—young age at diagnosis, increasing incidence, and
high survival rates—highlight the need for improved understanding of the variables influencing
the survivorship experience.
ETHODS Participants (n  116) were identified and recruited from the genitourinary services of 2 large
medical centers—one in the United States and the other in the Netherlands. Baseline assess-
ments were administered after diagnostic orchiectomy but before adjuvant treatment. Partici-
pants completed follow-up assessments after the completion of the chemotherapy regimen (or 3
months postdiagnosis for participants on surveillance regimens) and 12 months postdiagnosis.
The 36-Item Short-Form Health Survey was used to measure HRQOL.
ESULTS Findings indicated that men treated with chemotherapy reported significantly more bodily pain,
poorer role physical functioning, poorer social functioning, poorer physical health, more fatigue
compared with the men who did not receive chemotherapy at the post-treatment assessment. At
the time of 12 month follow-up, HRQOL scores did not vary by treatment group, and scores were
significantly higher than baseline HRQOL scores. No significant time by treatment group
interactions were observed at the 12 month follow-up.
ONCLUSIONS Results from this study indicate that chemotherapy is associated with only a temporary decrease in
HRQOL. Other HRQOL domains, including mental functioning, role emotional, and general health
perceptions, were not associated with treatment type at any of the assessment times. UROLOGY 75:




















aesticular cancer is the most frequently diagnosed
cancer among young men, with approximately
75% of cases occurring among men aged between
0 and 44 years.1 Incidence estimates vary by world
egion, but available data suggest that men from Europe
nd North America have a higher risk than men from
ther regions.2 In addition, evidence from numerous
ountries indicates that the incidence of testicular cancer
as been increasing over that past several decades.3,4
owever, effective treatment regimens are available, re-
ulting in 5-year survival rates of 95%.5 These unique
spects of testicular cancer—the young age at diagnosis,
ncreasing incidence, and high survival rates—highlight
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All Rights Reservedhe need for the exploration of health-related quality of
ife (HRQOL) outcomes in this growing population.
Treatment-related variables have been hypothesized to
nfluence the survivorship experience for men with tes-
icular cancer. Treatment approaches, including orchiec-
omy, adjuvant chemotherapy, radiation therapy, and
etroperitoneal lymph node dissection (RPLND), are typ-
cally based on disease stage and tumor histology.6,7 Each
f these approaches is associated with specific treatment-
elated side effects and late complications and, therefore,
ay negatively affect HRQOL.8
Several studies have attempted to both characterize
nd identify predictors of quality of life among testicular
ancer survivors in the past 25 years, including the sem-
nal work of Gritz et al.9 Recent comprehensive pub-
ished data reviews provide an overview of the find-
ngs.10,11 Although several studies have been designed to
xplore the association between treatment and HRQOL,
ertain characteristics of these studies create difficulty in
scertaining the true nature of this relationship. For ex-
mple, most studies have used cross-sectional designs,
nd numerous psychosocial outcome measures have been
















































































































Uhe participants in these studies, including such diverse
roups as newly diagnosed individuals and long-term
urvivors. Finally, many of these studies were conducted
ith relatively small samples, undoubtedly because of the
arity of testicular cancer.
Despite these issues with the existing published data,
everal trends have been fairly consistently observed.
imited evidence suggests that although treatment is
ssociated with a significantly increased risk of certain
reatment-related side-effects (eg, fertility, neurotoxicity,
nd Raynaud’s phenomena),10,12 post-treatment overall
uality of life may not be adversely affected by treatment
pproach.13-17 In addition, the few prospective studies
hat have been published suggest that although quality of
ife is adversely affected during adjuvant chemotherapy
nd radiation therapy, levels tend to return to baseline
fter the completion of treatment.16,18,19 However, sev-
ral reports suggest that survivors are more likely to
xperience some adverse outcomes, such as anxiety,20
hronic fatigue,21 and sexual dysfunction.22
In an effort to advance the understanding of the rela-
ionship between testicular cancer treatment and
RQOL, we conducted a prospective study with patients
ho were newly diagnosed with non–seminoma germ cell
umors (NSGCT) of the testis. Men were recruited from
large cancer centers. The purpose of the study was to
ompare HRQOL outcomes between men who received
treatment regimen consisting of orchiectomy and sur-
eillance with men who received orchiectomy plus adju-
ant chemotherapy.
ATERIAL AND METHODS
tudy Site and Participants
articipants were recruited from the genitourinary services of 2
niversity medical centers: the University of Texas MD Ander-
on Cancer Center (MDACC), Houston, Texas, and Univer-
ity Medical Center Groningen (UMCG), Groningen, the
etherlands. Consecutive patients with NSGCT were identi-
ed from daily reviews of clinic schedules. Other eligibility
riteria included: (1) age at diagnosis between 18 and 50 years;
2) English speaking and writing at MDACC and Dutch speak-
ng and writing at UMCG; and (3) ability of the patients to give
nformed consent. Exclusion criteria included: (1) prior neuro-
ogical disease or injury (eg, brain metastasis and closed head
njury); (2) extragonadal germ cell tumor; and (3) major psy-
hiatric illness. The study was reviewed and approved by the
nstitutional review boards of both MDACC and UMCG.
tudy Design and Objectives
articipants were recruited to the study after orchiectomy but
efore beginning adjuvant chemotherapy or a surveillance reg-
men. At the time of recruitment, socio-demographic, psycho-
ocial, and neurocognitive measures were administered. Partic-
pants completed a similar assessment approximately 1 week
fter the completion of adjuvant chemotherapy, or 3 months
fter baseline assessment for participants who did not receive
djuvant chemotherapy. A final assessment was completed 12
onths after the baseline assessment. In the current study, only t
ROLOGY 75 (3), 2010ata from the socio-demographic and psychosocial measures
ere considered.
easures
ocio-demographic characteristics considered included age at
he time of study enrollment, level of education, and marital
tatus. Because of differences in the Dutch and American edu-
ation systems, the education level was transformed into a
-category variable. For participants from MDACC, the cate-
ories were (1) high-school degree or less, (2) some college, and
3) 4-year college degree or more. Categories for UMCG par-
icipants were (1) low-level high school or vocational school or
ess, (2) midlevel high school or vocational degree, and (3)
igh-level high school or vocational degree or more.
HRQOL was assessed with the 36-Item Short-Form Health
urvey (SF-36) developed at RAND as part of the Medical
utcomes Study. This widely used and well-validated measure
ields 8 separate scale scores, including physical function, social
unction, pain, mental health, energy and/or fatigue, general
ealth perceptions, role limitations because of physical prob-
ems, and role limitations because of emotional problems.23-25
The Centers for Epidemiologic Studies - Depression was used
o assess depressive symptoms and is a well-validated 20-item
elf-report measure of depression that focuses on affective com-
onents, including feeling depressed, hopeless, fearful, or sad.
ound psychometric properties have been established with a
ide range of populations, including patient populations.26
nxiety was assessed using the state portion of the Spielberger
tate-Trait Anxiety Inventory, and it is a 20-item scale that
rovides information about a respondent’s current level of anx-
ety. This well-validated measure has been used widely in var-
ous clinical, medical, and general populations.27
Medical records were reviewed to confirm tumor pathology
nd treatment regimen. Additional medical data including dis-
ase stage and specific biomarker (ie, alpha-fetoprotein, human
horionic gonadotropin, and lactate dehydrogenase) were also
ollected from the MDACC participants.
The primary predictor variable of interest in this study was
reatment type. At UMCG, all men diagnosed of early stage
SGCT were placed on a surveillance regimen after orchiec-
omy, whereas men with more advanced NSGCT received 4
ycles of bleomycin, etoposide, and cisplatin (BEP), depending
n the Institutional gem Cell Consensus Classification.28 Ad-
uvant chemotherapy regimens administered at MDACC were
ore variable. Although BEP was by far the most common
egimen used, the number of cycles varied (ranging from 2 to
) based on tumor marker levels and the discretion of the
reating physician. For purposes of the current study, treatment
ype was dichotomized into surveillance or any chemotherapy.
n addition, RPLND was included as a covariate in all multi-
ariate analyses.
tatistical Analysis
escriptive statistics (means, medians, and frequencies) were
enerated for each of the demographic, disease, and treatment-
elated variables. The effect of treatment type (surveillance vs
djuvant chemotherapy) on the HRQOL outcomes at 3- and 12
onth follow-up was assessed with mixed-model ANCOVA
PROC mixed in SAS). Treatment type was modeled as a main
ffect and baseline value of HRQOL was included as a covari-
te. No significant predictors of HRQOL outcomes were iden-


































































6ovariates in the model. The specified approach provides esti-
ates of the treatment effect in terms of differences in baseline-
djusted means to detect the differential effect of the treatment
n the groups.
The long-term effects of treatment type were evaluated using
ongitudinal methods. Specifically, mixed model regression was
sed to model the average trend over time to analyze the
iffering patterns of change from baseline to 12 month fol-
ow-up between the surveillance and chemotherapy groups. A
onditional model was fit to the data to examine differences in
rends over time between the surveillance and chemotherapy
roups. In addition to the main effects of treatment and time,
ime by treatment interactions were included as fixed effects in
he model to test for differences in average rate of change over
ime between the 2 groups. The estimated slopes were compared
etween the treatment groups with Type III tests of fixed
ffects. The analysis was done with Proc Mixed (SAS) which
llows for unbalanced designs, missing data, and different co-
ariance structures. Adjustment for small sample correction was
one with the Kenward and Roger method.29
All modeling was done first by study site (MDACC and
MCG), and then with the combined sample. In all combined
nalyses, site was included as a covariate. All analyses were
onducted using SAS version 9.1 (SAS Institute, Inc., Cary,
C) and SPSS version 12.0 (SPSS, Inc., Chicago, IL).
ESULTS
total of 164 eligible men were identified at the 2 sites
100 at MDACC and 64 at UMCG). Of these, 116 men
70 at MDACC and 46 at UMCG; response, 70% and
2%, respectively) consented to participate in the study
nd completed a baseline assessment. Consent and as-
essment completion rates were similar at the 2 study
ites. At the time of study enrollment, participants from
DACC had a mean (SD) age of 31.0 (7.4) years and
Table 1. Baseline characteristics by study site for testicul
Characteristic
Age, mean (standard deviation)
Education, n (%)
High school or less-US/low-level high school or vocation
school or less-Dutch
Some college-US/mid-level or high degree or vocational
degree-Dutch
4-y college degree or higher-US/high-level high or
vocational degree or more-Dutch
Marital status, n (%)
Married or living with significant other
Single
Race/ethnic affiliation, n (%)
White
Nonwhite





Yespproximately two-thirds had completed at least some i
38ollege education. Participants from UMCG were
lightly younger, with a mean (SD) age of 27.9 (6.7)
ears, and approximately two-thirds of the Dutch partic-
pants reported having a midlevel high school, or voca-
ional degree, or higher level of education. Overall,
2.2% (n  61) of the participants reported being in a
ommitted relationship, although this proportion was
igher among the men from MDACC as compared with
hose from UMCG (58.6% vs 44.4%). Only 5 partici-
ants, all from MDACC, reported non–white race or
thnicity. A full description of the socio-demographic char-
cteristics of the participants can be found in Table 1.
The review of the medical record indicated that the
ajority (70%) of men at both recruitment sites re-
eived adjuvant chemotherapy after a diagnostic orchi-
ctomy. However, the proportion of men receiving
PLND was only 20% (n 14) at MDACC as compared
ith 47.8% (n  22) at UMCG.
ealth-Related Quality of Life at 3- and
2 Month Follow-Up by Treatment Group
RQOL outcomes, expressed as baseline adjusted mean
cores of the 8 SF-36 scales (ie, bodily pain, role physical,
ocial functioning, general health, mental health, physi-
al health, role emotional, and vitality), at the 3 month
ollow-up are displayed in Table 2. In general, HRQOL
as poorer for men in the chemotherapy than for men in
he surveillance group. Specifically, findings from the
ombined sample models indicated that men treated with
hemotherapy reported significantly more bodily pain,
oorer role physical functioning, poorer social function-
ng, poorer physical health, and more fatigue as compared
ith the men who did not receive chemotherapy. Find-
ncer patients enrolled in the study
The University of Texas
MD Anderson Cancer
Center, n  70
University Medical Center
Groningen, n  46
31.0 (7.4) 27.9 (6.7)
19 (27.1) 15 (32.6)
24 (34.3) 13 (28.3)
27 (38.6) 18 (39.2)
41 (58.6) 20 (44.4)
29 (41.4) 25 (55.6)
65 (92.9) 4 6(100)
5 (7.1) 0 (0)
15 (21.4) 12 (26.1)
55 (78.6) 34 (73.9)
56 (80.0) 24 (52.2)
14 (20.0) 22 (47.8)ar ca
alngs from the MDACC and UMCG site-specific analyses












































Undicated very similar trends, although not all differences
eached the level of statistical significance, most likely
ue to limited power. No significant differences by treat-
ent group were observed in the HRQOL domains of
ental health or role emotional functioning.
Results from the mixed-model regressions with the 12
onth HRQOL outcomes are presented in Table 3.
hese findings indicated that treatment group was not
ignificantly associated with any of the SF-36 scale scores.
ealth-Related Quality of Life
utcomes by Treatment Group Over Time
ixed effect coefficients, standard errors, and P values
rom the mixed models generated to examine the effects
f treatment group on the SF-36 HRQOL scale scores
ver time are presented in Table 4. The final models were
t using the conditional model with main effects of
reatment condition and time, along with treatment by
ime interaction terms. The coefficients of treatment by
ime terms provided estimates of the average rate of
hange from baseline to month 12 for the surveillance
nd chemo groups. Findings from the combined sample
nalyses revealed a significant main effect for time, with
Table 2. Adjusted mean (standard error) health-related qu
MD Anderson Cancer Center
U
Surveillance Chemotherapy Surv
(n  11) (n  49) (n
Bodily pain 87.2 (7.5) 68.9 (3.5)** 88.
Role physical 78.1 (13.0) 39.6 (6.2)*** 81.
Social functioning 83.3 (7.4) 70.9 (3.5) 82.
General health 69.3 (4.4) 68.8 (2.1) 73.
Mental health 74.6 (4.6) 75.3 (2.6) 78.
Physical health 87.8 (7.1) 76.9 (3.4) 89.
Role emotional 82.2 (11.6) 70.7 (5.5) 70.
Vitality 60.7 (6.0) 52.0 (2.9) 70.




Table 3. Adjusted mean (standard error) health-related qu
MD Anderson Cancer Center
Surveillance Chemotherapy Su
(n  9) (n  43) (
Bodily pain 90.3 (5.7) 87.7 (2.6) 8
Role physical 91.3 (9.3) 87.9 (4.2) 7
Social functioning 91.7 (4.9) 87.5 (2.2) 8
General Health 74.3 (5.4) 77.4 (2.5) 6
Mental health 80.6 (3.7) 79.2 (1.7) 7
Physical health 97.5 (4.7) 91.6 (2.2) 9
Role emotional 87.8 (9.7) 84.7 (4.4) 8
Vitality 69.6 (4.7) 66.7 (2.1) 6
* Follow-up scores adjusted for baseline scores.
** P .05.
*** P .01.
**** P .001.2 month HRQOL scale scores significantly higher than o
ROLOGY 75 (3), 2010aseline in both the surveillance and chemo groups on all
utcomes except in the general health domain. No sta-
istically significant time by treatment interactions for
ny of the HRQOL outcomes were observed. A compar-
son between the MDACC and UMCG samples revealed
imilar trends.
OMMENT
indings from this study indicated that as compared with
en placed on surveillance regimens, men who received
djuvant chemotherapy for NSGCT experienced a sta-
istically significant decrease in multiple dimensions of
RQOL (ie, physical health, role physical, bodily pain,
ocial functioning, and fatigue) in the period soon after
he completion of treatment. However, no significant
ifferences were observed at the time of 12 month follow-
p. Specifically, our results suggest that chemotherapy is
ssociated with only a temporary decrease in HRQOL.
lso, of note was the finding that HRQOL increased
ver the course of the year-long follow-up period.
RQOL scores at the time of the 12 month follow-up
ere significantly higher than baseline scores, regardless
of life scores at 3-month follow-up*
rsity Medical Center
Groningen Combined Sample
nce Chemotherapy Surveillance Chemotherapy
2) (n  28) (n  23) (n  77)
3) 73.1 (4.8) 87.2 (5.2) 71.0 (2.9)***
8) 15.1 (5.7)**** 80.5 (8.0) 28.5 (4.5)****
4) 64.7 (4.2)** 82.5 (4.9) 67.8 (2.7)***
6) 61.7 (2.4)*** 72.1 (2.9) 66.0 (1.6)
6) 73.7 (1.7) 76.5 (2.7) 74.8 (1.5)
9) 70.4 (3.8)*** 88.4 (4.7) 74.2 (2.6)***
.4) 60.3 (8.8) 76.5 (8.6) 65.4 (4.8)
4) 56.3 (2.9)** 65.3 (3.8) 54.1 (2.1)**
of life scores at 12-month follow-up*
rsity Medical Center
Groningen Combined Sample
lance Chemotherapy Surveillance Chemotherapy
12) (n  28) (n  21) (n  71)
3.9) 95.0 (2.5) 87.5 (3.4) 91.2 (1.9)
9.5) 84.4 (6.2) 85.0 (6.5) 85.8 (3.6)
4.5) 89.0 (2.9) 88.9 (3.3) 88.0 (1.8)
4.5) 75.2 (2.8) 71.8 (3.5) 76.5 (1.9)
3.4) 81.0 (2.2) 78.0 (2.5) 79.9 (1.4)
4.4) 92.6 (2.9) 93.4 (3.2) 92.0 (1.8)
7.2) 92.7 (4.7) 88.4 (5.9) 88.5 (3.3)











































































































6Other attempts to investigate the relationship between
esticular cancer treatment and HRQOL outcomes have
ielded conflicting findings. Several reviews published in
ecent years clearly document the various side effects
ssociated with cisplatin-based regimens typically used
or the treatment of NSGCT.8,10,11 Common side effects
nclude cardiovascular toxicity, increased risk of second
alignancy, infertility, ototoxicity, neurotoxicity, and
astrointestinal toxicity. However, existing evidence in-
icates that side effects are associated with poorer
RQOL, but treatment-type is not necessarily associated
ith HRQOL. For example, Mykletum et al30 conducted
large cross-sectional study of more than 1400 testicular
ancer survivors and approximately 2700 controls. Their
ndings indicated that at an average of 11 years from diag-
osis, treatment type was not associated with HRQOL. Side
ffects, however, were associated with HRQOL scores.
omewhat surprisingly, their results also indicated that
reatment type was not related to the side effects. Similar
esults have also been reported from smaller cross-sectional
tudies of testicular cancer survivors.13,15
Although findings from the more rigorously designed
ross-sectional studies suggest that treatment type may not
e an important factor in the long term quality of life of
esticular cancer survivors, findings from prospective studies
re required to more definitively address this research ques-
ion. To our knowledge, however, very few prospective
tudies have been conducted. Fossa et al16 conducted one
f the few studies using data collected from patients
nrolled in a clinical trial conducted through the Euro-
ean Organization for Research and Treatment of Can-
er. In this study, the authors compared HRQOL out-
omes among men treated with 4 different chemotherapy
egimens. Very similar to our findings, Fossa et al ob-
erved that HRQOL scale scores dropped during and
mmediately after chemotherapy administration, but fully
ecovered by the time of 12- and 24 month follow-ups.
heir results also indicated that treatment type had no
ffect on HRQOL scores. Because all the men in the trial
ere treated with very similar regimens (3 cycles of BEP
s 3 cycles of BEP plus one cycle of etoposide and
isplatin delivered over 3 or 5 days), the failure to ob-
erve treatment group differences is not overly surprising.






Bodily pain 14.3 (2.4) .0001
Role physical 23.1 (4.0) .0001
Social functioning 10.3 (2.1) .0001
General Health 1.1 (1.5) .4745
Mental health 4.7 (1.2) .0009
Physical health 3.9 (1.9) .0430
Role emotional 9.9 (3.2) .0026
Vitality 4.6 (1.7) .0088rask et al also published results from a small pilot trial s
40esigned to prospectively explore HRQOL among men
ith newly diagnosed testicular cancer. Similar to the
ther findings, the authors found that HRQOL drops
uring and immediately after chemotherapy, but tends to
ecover to baseline levels by 8 months postbaseline. Be-
ause this study was a pilot investigation, no comparison
roups were available.
Our attempt to investigate the relationship between
reatment and HRQOL among men with testicular can-
er offers several important contributions. First, we used
prospective study design, with pre-chemotherapy assess-
ent, a postchemotherapy (or 3 months postbaseline for
he participants in the surveillance group) follow-up, and
2 month follow-up. Second, unlike other prospective
tudies of HRQOL outcomes, we included men receiving
hemotherapy and men who were followed up with a
urveillance regimen. Therefore, our study was able to
ffer a more direct assessment of the short-term effects of
hemotherapy than the previous efforts. In addition, the
resent study recruited men from cancer centers located
n 2 diverse sites—Houston, Texas, and Groningen, the
etherlands. Despite possible socio-cultural differences
etween these 2 locations, we observed an almost iden-
ical pattern in HRQOL scale scores.
The prospective study design and the inclusion of a
urveillance-only treatment group were important
trengths of the current study. However, several limita-
ions should be considered when interpreting the find-
ngs. First, the men receiving chemotherapy at MDACC
ere placed on various regimens, ranging from 2-7 cycles.
herefore, our approach which involved grouping all
en who received chemotherapy into the same category
id not allow a true dose–response assessment of the
ffects of chemotherapy. To partially address this prob-
em, we performed exploratory analyses (not presented)
ith the MDACC sample in which various categories of
hemotherapy (based on number of cycles received) were
sed. These exploratory analyses yielded consistent find-
ngs. That is, regardless of the operational definition of
he chemotherapy group, men who receive chemother-
py experience a significant decrease in HRQOL scores
mmediately after treatment completion (compared with
en who do not receive chemotherapy), but HRQOL







3 (2.5) .0001 14.3 (1.7) .00001
7 (4.2) .0001 24.2 (2.9) .0001
7 (2.5) .0023 9.2 (1.6) .0001
9 (1.9) .1317 1.9 (1.2) .1172
9 (1.3) .0004 4.9 (1.0) .0001
6 (2.4) .0520 4.2 (1.5) .0049
1 (4.3) .0059 10.9 (2.7) .0001











3.cores recover to levels above the baseline scores at the

















































Uime of 12 month follow-up. The lack of a primary
PLND group may have also limited our ability to sep-
rate surgical- and chemotherapy-related effects.
Another limitation was the unavailability of complete
edical data, including detailed staging and biomarker
evels from participants at the UMCG site. However,
xploratory analyses (not presented) using the detailed
taging and tumor marked data available from the
DACC participants indicated that these variables were
ot significant predictors of the post chemotherapy drops
n HRQOL scores after treatment group was included in
he models, nor were they predictive of 12-month out-
omes.
A final limitation of note involves the measure of
RQOL used in this study—the SF-36. Although this is
widely used and well-validated measure of generic
RQOL, is was not designed to tap all functional do-
ains that may have been affected by testicular cancer
reatment. Therefore, the use of a testicular cancer-spe-
ific measure may have provided more insight about the
ong-term effects of treatment.
In conclusion, our results confirm the finding that men
reated with chemotherapy experience a significant, but
emporary drop in HRQOL. These findings may be help-
ul both to patients with newly diagnosed NSGCT and to
linicians. Specifically, clinicians may be able to better
nform the patients about the expected decline in
RQOL associated with chemotherapy, while offering
eassurance about the temporary nature of these declines.
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